Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and safety of chromatographically purified vero cell rabies vaccine in 2-dose pre-exposure schedule in infants and children
TCTR20240530003Phase 3Completed
- Sponsor
- Liaoning Chengda Biotechnology Co., Ltd.
- Start
- Jul 2020
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, single-arm trial of Rabies vaccine in rabies, sponsored by Liaoning Chengda Biotechnology Co., Ltd. Primary endpoints: Immunogenicity of chromatographically purified vero cell rabies vaccine and Safety of chromatographically purified vero cell rabies vaccine. Started Jul 2020; status: completed.
02
Drugs
Rabies vaccine
03
Conditions
rabies
Beyond the preview
Go deeper on TCTR20240530003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20240530003.